Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.
http://www.priceseries.com/trade/KIN-Kindred-Biosciences-Inc-stock-gains-44-percent-a-Trade-Record-by-priceSeries-2021061520210715.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments